Business
Inspira™ Signs Term Sheet for Use of INSPIRA™ ART100 Device in Organ Transplant Procedures
RA'ANANA, Israel, April 16, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a
About this update from Qtrex Quantum Ltd.
[{"type":"text","content":"RA'ANANA, Israel, April 16, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the \"Company\" or \"Inspira\"), a breakthrough medical technology company, is proud to announce the signing of a collaboration term sheet (the \"Term Sheet\") with the Beilinson Hospital in Israel for the evaluation of its proprietary INSPIRA ART100 device (the \"Device\") in organ transplant procedures. This Term Sheet marks a significant advancement and opportunity for the Company in its technology being extended for use in additional medical segments and markets.\n\n \n \nUnder the evaluation agreement contemplated by the Term Sheet, the hospital shall provide Inspira with access to the internally logged data and diagnostics from the use of the Device and user feedback from medical doctors, certified clinical perfusionists, and other caregivers. The data is intended to be freely used by Inspira.\nBeilinson Hospital is the leading organ transplant center in Israel, conducting over 70% of the organ transplants in Israel. To date, it has performed thousands of procedures, including more than 900 lung transplants. As a pioneering institution in kidney, lung, heart, liver, and pancreas transplants, the Beilinson Hospital oversees multiple organ donor programs and is involved in international research studies.\nThe progression of the Term Sheet is subject to the subsequent formalization of a detailed definitive evaluation agreement between the parties.\nDr. Dan Gorfil, the head of the Cardiothoracic Surgery Intensive Care Unit and the Extracorporeal Membrane Oxygenation program at the Department of Cardiothoracic Surgery at Beilinson Hospital, stated: \"As physicians, our foremost commitment is to our patients' well-being. Partnering with Inspira to assess the INSPIRA ART100 device in organ transplant procedures aligns with this commitment. This collaboration has the potential to enhance patient outcomes, offering hope and possibility in the realm of organ transplants.\"\nThe Term Sheet addresses the use of Inspira's proprietary INSPIRA ART100 device in medical procedures in intensive care units for life support and operating rooms to support organ transplants. The primary objectives of the evaluation agreement are to assess the functionality and performance of the Device in clinical settings and healthcare delive...